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PERSPE C T I V E

The Moral of the Story

sion about a child who doesn’t
seem critically ill. You can’t let all
the what-ifs terrorize you, or you
would do a lumbar puncture on
every young child with a high fever
and do a CT scan for even the
most minor bump on the head. So
you just go on practicing, haunted
by stories — stories you’re a part
of, stories that happen to people
you love or know well or take
care of, stories you hear from your
teachers and colleagues, and the
occasional well-told story that enters your brain and lives there . . .
all those ghosts that hover at your
shoulder or in the dark places of

your mind. I had a peculiar sense
of multiple levels of precepting
— of me standing over the intern, and my preceptor standing
over me, and of the ways that your
medical education comes down
to you partly from people you will
never meet.
I’d like to think of it, in part, as
a collective medical memory. And
also as a way of honoring the patients who have suffered “bad
outcomes” — and their physicians,
too, the ones who are grieving
still, who have told and retold
these difficult stories. Bad things
can be only a step away, and we

need to absorb that knowledge
and yet still do our job. It seems
to me right and proper that even
in everyday primary care, there
should arise these unexpected,
unpredictable moments when the
collective memory catches at your
sleeve, when the ghosts whisper to
you to watch out, to think again,
or at least to scribble a cell-phone
number on a piece of paper towel
and call later just to be sure that
everything’s truly okay.
No potential conflict of interest relevant
to this article was reported.
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n November 1996, the Wall Street
Journal reported that Eli Lilly was
paying homeless alcoholics from a
local shelter to participate in safety
testing of new drugs at its trial site
in Indianapolis.1 “These individuals want to help society,” asserted
Lilly’s director of clinical pharmacology. The subjects, however, said
they took part for easy money and
free room and board. Although
Lilly reportedly offered the lowest
per diem in the business, it managed to attract poor subjects from
all over the country.1 The medical
director of the local Homeless
Initiative Program said Lilly had
created a “shadow economy” of
paid human subjects.
Today, the Lilly episode seems
like an early warning about an
emerging set of ethical problems.
Over the past decade, clinical trials have moved from universities
to private testing sites, the pressure to recruit subjects quickly has
intensified, and ethical oversight
has been outsourced to for-profit
institutional review boards (IRBs).
Payment to subjects has escalated,
2316

creating “shadow economies” in
cities throughout North America
and elsewhere. In 2005, Bloomberg Markets reported that SFBC
International, a contract research
organization, was paying immigrants to participate in drug trials
under ethically questionable conditions in a dilapidated Miami motel. A few months later, nine apparently previously healthy subjects
at an SFBC subsidiary in Montreal
contracted latent tuberculosis during a trial of an immunosuppressant. In 2006, six healthy subjects
required intensive care in a phase
1 trial of a monoclonal antibody at
a London facility run by the contract research organization Parexel.
For all the ethical debate over these
cases, however, few commentators have addressed the most
troubling question: Is it ethically
problematic to pay poor people
to test the safety of new drugs?
Paying study subjects is not a
new practice, but neither is it uncontroversial. According to regulators, payment should not be
so high as to become an “undue
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inducement,” lest subjects enroll
in risky, unpleasant, or degrading
trials against their better judgment. But this standard gives IRBs
little practical guidance: a sum of
money that the wealthy can easily
resist may be very tempting for
poorer people. Keeping payments
low, however, seems unfair to
the poor, who submit to trials
precisely because they need the
money. And whether or not such
people are being unduly induced,
the larger question is whether they
are being exploited.
To exploit people is to take unfair advantage of them, but there is
no consensus that current trial arrangements are unfair. Defenders
of the status quo argue that people
who enroll in trials have agreed to
their conditions, that they get paid
enough to make it worth their
while, and that they are made better off by the arrangement. Nevertheless, there are good reasons
to believe that poor subjects are
being exploited.
First, poor people are less likely
than wealthier ones to get access
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to the drugs in question, if and
when they are approved. Volunteers are unlikely to have full-time
employment or, therefore, to have
health insurance. Placing the burden of safety testing on the poor
appears to contravene article 19 of
the Declaration of Helsinki, which
states that medical research is ethically justified only if there is a
reasonable chance that the population in which it is conducted
will benefit from the results.
Second, the U.S. oversight system is not well equipped to monitor a highly competitive, marketbased, multinational research
industry. The Office for Human
Research Protections has no jurisdiction over privately sponsored
studies, and the Food and Drug
Administration inspects only about
1% of clinical trials.2 IRBs, the
most important bodies charged
with protecting subjects, were designed primarily to review trial design, risk–benefit ratios, and informed-consent documents. Recent
research scandals — which have
been uncovered largely by investigative reporters rather than regulators — have concerned a very
different set of issues: fraud, conflicts of interest, unfair payment
practices, and unsafe or degrading
trial conditions. Such problems are
magnified still further when studies are conducted at private testing
sites and reviewed by for-profit
IRBs that are financially dependent on research sponsors.
Third, even though the purpose
of phase 1 trials is to test whether
new drugs are safe, most sponsors
apparently do not provide free care
or treatment for subjects who are
injured in these trials. In fact, no
agency is even tracking injuries in
phase 1 trials, much less the longterm health of people who volunteer for many trials over a period of
years. A recent study commissioned
by the Department of Health and

Human Services showed that only
16% of academic health centers
provide injured subjects with free
care. None compensate injured
subjects for pain and suffering or
lost wages.3 Although no comparable data are available for private
research sponsors, there is little
reason to believe that private sponsors are much more generous4;
indeed, many include disclaimers
in their consent forms indicating
that subjects retain responsibility
for their own medical care.
Most of these problems can be
seen as consequences of the transformation of clinical research into
a business. Many subjects in phase
1 trials today see their participation as a job.5 They must pay taxes
on their trial income, and sponsors often require them to sign a
form acknowledging their status
as “independent contractors.” The
payment has become high enough
to make participating in trials
more lucrative than holding a minimum-wage job, even if subjects
abide by the requirement that they
wait 30 days between trials. Yet
subjects get none of the rights or
benefits that come with a good
job, such as workers’ compensation, the right to unionize, disability benefits, or health insurance.
Subjects whose livelihoods depend
on trial income are often reluctant
to drop out of trials that turn out
to be risky or unpleasant, especially if they have traveled some
distance to the trial site and have
invested a substantial amount of
money in accommodations while
waiting to enter the trial. Subjects
have little incentive to be truthful about their medical history or
health status because known medical problems may preclude their
participation in a study. Nor do
they have anyone to go to with
complaints. Many say they are reluctant to complain to sponsors
about poor conditions for fear
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of being excluded from future trials. For similar reasons, they are
reluctant to go to a lawyer, even
if a trial goes seriously wrong.4
Without actually intending to
do so, policymakers have allowed
participation in clinical trials to
become something very close to a
job. Sponsors call subjects’ payments “compensation” to suggest
that they are merely reimbursing
participants for expenses and inconvenience, even as they fill studies with unemployed people who
depend on trial income to make
ends meet. They refer to paid subjects as “volunteers,” implying that
participation is a freely chosen act
of altruism, whereas most subjects
indicate that they take part in
trials for the money. Regulators
allow sponsors to use money to
attract subjects but do not require
them to provide the kinds of benefits that subjects would demand
if they had more power. The result
is what one Philadelphia trial subject describes as “a mild torture
economy.” “You are not being paid
to do something,” he explains.
“You are being paid to endure.”5
No potential conflict of interest relevant
to this article was reported.
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